Welcome to the BiDil Clinical Resource page. We understand that Healthcare Providers need to make daily decisions based on solid clinical data. This page has been organized to provide helpful information about BiDil and the benefits it provides for African American patients with heart failure. You are welcome to view each icon or download it for future use.

HEALTH CARE PROVIDER RESOURCES

Medical Affairs
If you have any questions regarding the use of BiDil please contact Medical Affairs at 888-692-4345.

BiDil's Clinical Story
This slide presentation provides a comprehensive view of heart failure in African-Americans, A-HeFT and the use of BiDil.

Clinical Pharmacokinetics Reprint
Leading heart failure specialists, Dr. Jay Cohn and Dr. Milton Packer, are among the authors who investigated the different formulations and demonstrated a lack of bioequivalence between BiDil vs. the individual components of isosorbide dinitrate and hydralazine.

There are No Generic Equivalents for BiDil - The Evidence
This slide presentation highlights the differences between BiDil vs. ISDN and hydralazine.

African-American Heart Failure Trial
Click on this icon to view and download this landmark publication that highlights the benefits of BiDil for the treatment of heart failure in African Americans.

BiDil Dosage and Administration
Click on this icon to view or download helpful tips for the dosing and administration of BiDil.

FDA letter confirming no generic equivalents to BiDil
Click on this icon to view or download the FDA letter that states there are currently no generic equivalents to BiDil.

Important information about BiDil®
(isosorbide dinitrate/hydralazine hydrochloride):

INDICATIONS AND USAGE
BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.

CONTRAINDICATIONS
BiDil is contraindicated in patients who are allergic to organic nitrates.

WARNINGS
Augmentation of the vasodilatory effects of isosorbide dinitrate by phosphodiesterase inhibitors such as sildenafil, vardenafil, or tadalafil could result in severe hypotension. The time course and dose dependence of this interaction have not been studied. Reasonable supportive care should consist of those measures used to treat a nitrate overdose with elevation of the extremities and central volume expansion.

ADVERSE REACTIONS
Adverse events reported in A-HeFT and seen more frequently in the group given BiDil included headache (50% in BiDil patients vs. 21% in placebo patients) and dizziness (32% in BiDil patients vs. 14% in placebo patients).

The full Prescribing Information for BiDil is available here.